Type 2 Biomarkers and Eosinophil Activation in Severe Asthma and the Impact of Mepolizumab

被引：0
|
作者：
Howarth, P. [1 ]
Quirce, S. [2 ,3 ]
Papi, A. [4 ,5 ]
Israel, E. [6 ,7 ]
Mallett, S. [8 ]
Bates, S. [9 ]
Albers, F. C. [10 ]
Kwon, N. [11 ]
机构：
[1] GSK House, Global Med Franchise, Brentford, England
[2] Hosp La Paz Inst Hlth Res IdiPAZ, Dept Allergy, Madrid, Spain
[3] Inst Carlos III, CIBERES, Madrid, Spain
[4] Univ Ferrara, Dept Med Sci, Ferrara, Italy
[5] S Anna Univ Hosp, Ferrara, Italy
[6] Harvard Med Sch, Boston, MA 02115 USA
[7] Brigham & Womens Hosp, Asthma Res Ctr, 75 Francis St, Boston, MA 02115 USA
[8] GSK, Biostat, Stockley Pk, Uxbridge, Middx, England
[9] GSK, Resp Discovery Med, Stevenage, Herts, England
[10] GSK, Resp Med Franchise, Res Triangle Pk, NC USA
[11] GSK, Resp Med Franchise, London, England
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1275
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Eosinophil miRNAs as biomarkers in asthma
    Canas, J. A.
    Sastre, B.
    Mazzeo, C.
    Guerra, A.
    Rego, N.
    Greif, G.
    Barranco, P.
    Quirce, S.
    Sastre, J.
    del Pozo, V
    ALLERGY, 2016, 71 : 6 - 7
  • [22] Impact of mepolizumab on work productivity and activity impairment in severe eosinophilic asthma
    Gunsoy, Necdet B.
    Cockle, Sarah M.
    Albers, Frank C.
    Doyle, Scott
    Cristancho, Rafael Alfonso
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [23] Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
    Bagnasco, Diego
    Povero, Massimiliano
    Pradelli, Lorenzo
    Brussino, Luisa
    Rolla, Giovanni
    Caminati, Marco
    Menzella, Francesco
    Heffler, Enrico
    Canonica, Giorgio Walter
    Paggiaro, Pierluigi
    Senna, Gianenrico
    Milanese, Manlio
    Lombardi, Carlo
    Bucca, Caterina
    Manfredi, Andrea
    Canevari, Rikki Frank
    Passalacqua, Giovanni
    WORLD ALLERGY ORGANIZATION JOURNAL, 2021, 14 (02):
  • [24] Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma
    Albers, Frank C.
    Licskai, Christopher
    Chanez, Pascal
    Bratton, Daniel J.
    Bradford, Eric S.
    Yancey, Steven W.
    Kwon, Namhee
    Quirce, Santiago
    RESPIRATORY MEDICINE, 2019, 159
  • [25] Mepolizumab (Nucala) for Severe Eosinophilic Asthma
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1486): : 11 - 12
  • [26] Mepolizumab for the treatment of severe eosinophilic asthma
    Poulakos, Mara N.
    Cargill, Shawna M.
    Waineo, Melissa F.
    Wolford, Allen L., Jr.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2017, 74 (13) : 963 - 969
  • [27] Mepolizumab in the treatment of severe eosinophilic asthma
    Fainardi, Valentina
    Pisi, Giovanna
    Chetta, Alfredo
    IMMUNOTHERAPY, 2016, 8 (01) : 27 - 34
  • [28] An evaluation of mepolizumab for the treatment of severe asthma
    Morjaria, Jaymin B.
    Emma, Rosalia
    Fuochi, Virginia
    Polosa, Riccardo
    Caruso, Massimo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (06) : 491 - 500
  • [29] Trajectories of responses to mepolizumab in severe asthma
    Nolasco, Santi
    Mukherjee, Manali
    Nair, Parameswaran
    EUROPEAN RESPIRATORY JOURNAL, 2025, 65 (01)
  • [30] Severe Pediatric Asthma Therapy: Mepolizumab
    Ullmann, Nicola
    Peri, Francesca
    Florio, Olivia
    Porcaro, Federica
    Profeti, Elisa
    Onofri, Alessandro
    Cutrera, Renato
    FRONTIERS IN PEDIATRICS, 2022, 10
12345